Risk Minimisation Materials

CHECKLIST FOR PRESCRIBERS

Checklist to be used in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

For Healthcare Professionals

Important information for women

Further information about the recommendations coming from a recent Europe-wide review of the safety of combined hormonal contraceptives, in particular the risk of blood clots.

RISK OF BLOOD CLOTS

IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Yervoy (ipilimumab) Healthcare Professional Digital Risk Minimisation Material Platform

The Healthcare Professional (HCP) Platform is based on the UK ipilimumab paper based HCP risk minimisation materials

For Healthcare Professionals

Yervoy (ipilimumab) Patient Alert Card

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before you are given Yervoy (ipilimumab) and during treatment with Yervoy (ipilimumab).

Yervoy (ipilimumab) Patient Digital Risk Minimisation Material Platform

The Patient Platform is based on the UK ipilimumab paper based Patient risk minimisation materials

Yervoy (ipilimumab) Patient Information Guide

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information.

Yervoy (ipilimumab) Risk Minimisation Information for Healthcare Professionals Guide for Prescribing

This risk minimisation material is a condition of the marketing authorisation. If you would like a hard copy of the Yervoy (ipilimumab) risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; e-mail: [email protected]) with your specific request.

For Healthcare Professionals

YESCARTA_Handling Guide

Guide to handling and method of administration: To minimize the potential risk of decrease in viability of the product loss of efficacy due to inappropriate preparation of the Yescarta infusion.

For Healthcare Professionals

YESCARTA_HCP educational guide

Healthcare provider (HCP) educational material - To inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions, and provide guidance on reporting these serious adverse reactions associated with Yescarta.

For Healthcare Professionals

YESCARTA_Patient Alert Card

Patient Alert Card - To inform patients of the risks of CRS and serious neurologic adverse reactions, associated with Yescarta.